| Original language | English (US) |
|---|---|
| Article number | e008587 |
| Journal | Journal of the American Heart Association |
| Volume | 7 |
| Issue number | 14 |
| DOIs | |
| State | Published - Jul 1 2018 |
Keywords
- Congenital heart disease
- Pulmonary atresia
- Pulmonary hypertension
- Segmental pulmonary hypertension
- Truncus arteriosus
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Definition and management of segmental pulmonary hypertension. / Dimopoulos, Konstantinos; Diller, Gerhard Paul; Opotowsky, Alexander R.; D’Alto, Michele; Gu, Hong; Giannakoulas, George; Budts, Werner; Broberg, Craig S.; Veldtman, Gruschen; Swan, Lorna; Beghetti, Maurice; Gatzoulis, Michael A.
In: Journal of the American Heart Association, Vol. 7, No. 14, e008587, 01.07.2018.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Definition and management of segmental pulmonary hypertension
AU - Dimopoulos, Konstantinos
AU - Diller, Gerhard Paul
AU - Opotowsky, Alexander R.
AU - D’Alto, Michele
AU - Gu, Hong
AU - Giannakoulas, George
AU - Budts, Werner
AU - Broberg, Craig S.
AU - Veldtman, Gruschen
AU - Swan, Lorna
AU - Beghetti, Maurice
AU - Gatzoulis, Michael A.
N1 - Funding Information: advisory boards of Actelion, Germany. Opotowsky has received research grants from Actelion and Roche Diagnostics and has consulted for Novartis. D’Alto has served on the advisory board of Actelion, Bayer, United Therapeutics, and GlaxoSmithKline. Gu has received research grants from Actelion. Giannakoulas has acted as a consultant and/or received unrestricted educational or research grants from Actelion, Bayer, MSD, GlaxoSmithKline, Lilly, Pfizer, and United Therapeutics. Budts received a research grant from Actelion. Veldtman received a single research support from United Therapeutics. Beghetti has served as a consultant and/or advisory board member for Actelion, Bayer, Eli Lilly, GlaxoSmithKline, Novartis, and Pfizer and has received investigator-initiated research funding from Actelion and Bayer. Gatzoulis has acted as a consultant and received unrestricted educational or research grants from Bayer UK, Pfizer, and Actelion. The remaining authors have no disclosures to report.
PY - 2018/7/1
Y1 - 2018/7/1
KW - Congenital heart disease
KW - Pulmonary atresia
KW - Pulmonary hypertension
KW - Segmental pulmonary hypertension
KW - Truncus arteriosus
UR - http://www.scopus.com/inward/record.url?scp=85050490944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050490944&partnerID=8YFLogxK
U2 - 10.1161/JAHA.118.008587
DO - 10.1161/JAHA.118.008587
M3 - Article
C2 - 29973393
AN - SCOPUS:85050490944
VL - 7
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
SN - 2047-9980
IS - 14
M1 - e008587
ER -